Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
9 "Ji Eun Jun"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Brief Report
Metabolic Risk/Epidemiology
Trends in the Prevalence of Obesity and Its Phenotypes Based on the Korea National Health and Nutrition Examination Survey from 2007 to 2017 in Korea
Sang Ouk Chin, You-Cheol Hwang, Hong-Yup Ahn, Ji Eun Jun, In-Kyung Jeong, Kyu Jeung Ahn, Ho Yeon Chung
Diabetes Metab J. 2022;46(5):808-812.   Published online March 8, 2022
DOI: https://doi.org/10.4093/dmj.2021.0226
  • 3,069 View
  • 199 Download
  • 2 Citations
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
This study used data from the Korea National Health and Nutrition Examination Survey IV–VII from 2007 to identify the prevalence of obesity and its phenotypes (metabolically unhealthy obesity [MUO] and metabolically healthy obesity [MHO]) and their secular changes. The prevalence of obesity in Korea increased with significant secular changes observed (β=0.326, P trend <0.01) between 2007 and 2017, and especially in men (β=0.682, P trend <0.001) but not in women. The changes in the prevalence of obesity during the study period were different between men and women (P=0.001). The prevalence of MUO significantly increased only in men (β=0.565, P trend <0.01), while that of MHO increased only in women (β=0.179, P<0.05), especially in the younger age group (β=0.308, P<0.01).

Citations

Citations to this article as recorded by  
  • Hormonal Gut–Brain Signaling for the Treatment of Obesity
    Eun Roh, Kyung Mook Choi
    International Journal of Molecular Sciences.2023; 24(4): 3384.     CrossRef
  • Differences of Regional Fat Distribution Measured by Magnetic Resonance Imaging According to Obese Phenotype in Koreans
    Ha-Neul Choi, Hyunjung Lim, Young-Seol Kim, Sang-Youl Rhee, Jung-Eun Yim
    Metabolic Syndrome and Related Disorders.2022; 20(10): 551.     CrossRef
Original Articles
Metabolic Risk/Epidemiology
Increased Visit-to-Visit Liver Enzyme Variability Is Associated with Incident Diabetes: A Community-Based 12-Year Prospective Cohort Study
Kyuhoon Bang, Ji Eun Jun, In-Kyung Jeong, Kyu Jeung Ahn, Ho Yeon Chung, You-Cheol Hwang
Diabetes Metab J. 2021;45(6):890-898.   Published online March 17, 2021
DOI: https://doi.org/10.4093/dmj.2020.0208
  • 4,238 View
  • 147 Download
Graphical AbstractGraphical Abstract AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Fatty liver and/or increased liver enzyme values have been reported to be associated with incident diabetes. We sought to determine whether increased visit-to-visit liver enzyme variability is associated with incident diabetes.
Methods
Study participants were recruited from the Korean Genome and Epidemiologic Study (KoGES). A total of 4,151 people aged 40 to 69 years was recruited and tested every 2 years for up to 12 years. Visit-to-visit aspartate aminotransferase (AST) and alanine aminotransferase (ALT) variability was evaluated in first the 6-year period through the use of various variability measurements: standard deviation (SD), average successive variability, coefficient of variation (CV), and variation independent of mean (VIM). Oral glucose tolerance test was performed at every visit.
Results
During the 6-year follow‐up appointments, 13.0% (538/4,151) of people developed incident diabetes. Visit-to-visit AST variability was associated with an increased risk of diabetes independent of conventional risk factors for diabetes (hazard ratio per 1-SD increment [95% confidence interval]: 1.06 [1.00 to 1.11], 1.12 [1.04 to 1.21], and 1.13 [1.04 to 1.22] for SD, CV, and VIM, respectively; all P<0.05); however, no such associations were observed in the visit-to-visit ALT variability. According to alcohol consumption status, both AST and ALT variability were independent predictors for incident diabetes in subjects with heavy alcohol consumption; however, neither AST nor ALT variability was associated with diabetes risk in subjects who did not drink alcohol heavily.
Conclusion
Visit-to-visit liver enzyme variability is an independent predictor of incident diabetes. Such association was more evident in those who consumed significant amounts of alcohol.
Complications
Association of Urinary N-Acetyl-β-D-Glucosaminidase with Cardiovascular Autonomic Neuropathy in Type 1 Diabetes Mellitus without Nephropathy
Min Sun Choi, Ji Eun Jun, Sung Woon Park, Jee Hee Yoo, Jiyeon Ahn, Gyuri Kim, Sang-Man Jin, Kyu Yeon Hur, Moon-Kyu Lee, Jae Hyeon Kim
Diabetes Metab J. 2021;45(3):349-357.   Published online February 2, 2021
DOI: https://doi.org/10.4093/dmj.2019.0211
  • 4,938 View
  • 117 Download
  • 1 Citations
Graphical AbstractGraphical Abstract AbstractAbstract PDFPubReader   ePub   
Background
Cardiovascular autonomic neuropathy (CAN) is a common microvascular complication of diabetes and related to albuminuria in diabetic nephropathy (DN). Urinary N-acetyl-β-D-glucosaminidase (uNAG) is a renal tubular injury marker which has been reported as an early marker of DN even in patients with normoalbuminuria. This study evaluated whether uNAG is associated with the presence and severity of CAN in patients with type 1 diabetes mellitus (T1DM) without nephropathy.
Methods
This cross-sectional study comprised 247 subjects with T1DM without chronic kidney disease and albuminuria who had results for both uNAG and autonomic function tests within 3 months. The presence of CAN was assessed by age-dependent reference values for four autonomic function tests. Total CAN score was assessed as the sum of the partial points of five cardiovascular reflex tests and was used to estimatethe severity of CAN. The correlations between uNAG and heart rate variability (HRV) parameters were analyzed.
Results
The association between log-uNAG and presence of CAN was significant in a multivariate logistic regression model (adjusted odds ratio, 2.39; 95% confidence interval [CI], 1.08 to 5.28; P=0.031). Total CAN score was positively associated with loguNAG (β=0.261, P=0.026) in the multivariate linear regression model. Log-uNAG was inversely correlated with frequency-domain and time-domain indices of HRV.
Conclusion
This study verified the association of uNAG with presence and severity of CAN and changes in HRV in T1DM patients without nephropathy. The potential role of uNAG should be further assessed for high-risk patients for CAN in T1DM patients without nephropathy.

Citations

Citations to this article as recorded by  
  • Association between carotid atherosclerosis and presence of intracranial atherosclerosis using three-dimensional high-resolution vessel wall magnetic resonance imaging in asymptomatic patients with type 2 diabetes
    Ji Eun Jun, You-Cheol Hwang, Kyu Jeong Ahn, Ho Yeon Chung, Geon-Ho Jahng, Soonchan Park, In-Kyung Jeong, Chang-Woo Ryu
    Diabetes Research and Clinical Practice.2022; 191: 110067.     CrossRef
Drug/Regimen
Efficacy and Safety of Omega-3 Fatty Acids in Patients Treated with Statins for Residual Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Ji Eun Jun, In-Kyung Jeong, Jae Myung Yu, Sung Rae Kim, In Kye Lee, Kyung-Ah Han, Sung Hee Choi, Soo-Kyung Kim, Hyeong Kyu Park, Ji-Oh Mok, Yong-ho Lee, Hyuk-Sang Kwon, So Hun Kim, Ho-Cheol Kang, Sang Ah Lee, Chang Beom Lee, Kyung Mook Choi, Sung-Ho Her, Won Yong Shin, Mi-Seung Shin, Hyo-Suk Ahn, Seung Ho Kang, Jin-Man Cho, Sang-Ho Jo, Tae-Joon Cha, Seok Yeon Kim, Kyung Heon Won, Dong-Bin Kim, Jae Hyuk Lee, Moon-Kyu Lee
Diabetes Metab J. 2020;44(1):78-90.   Published online June 20, 2019
DOI: https://doi.org/10.4093/dmj.2018.0265
  • 7,734 View
  • 164 Download
  • 7 Citations
AbstractAbstract PDFSupplementary MaterialPubReader   
Background

Cardiovascular risk remains increased despite optimal low density lipoprotein cholesterol (LDL-C) level induced by intensive statin therapy. Therefore, recent guidelines recommend non-high density lipoprotein cholesterol (non-HDL-C) as a secondary target for preventing cardiovascular events. The aim of this study was to assess the efficacy and tolerability of omega-3 fatty acids (OM3-FAs) in combination with atorvastatin compared to atorvastatin alone in patients with mixed dyslipidemia.

Methods

This randomized, double-blind, placebo-controlled, parallel-group, and phase III multicenter study included adults with fasting triglyceride (TG) levels ≥200 and <500 mg/dL and LDL-C levels <110 mg/dL. Eligible subjects were randomized to ATOMEGA (OM3-FAs 4,000 mg plus atorvastatin calcium 20 mg) or atorvastatin 20 mg plus placebo groups. The primary efficacy endpoints were the percent changes in TG and non-HDL-C levels from baseline at the end of treatment.

Results

After 8 weeks of treatment, the percent changes from baseline in TG (−29.8% vs. 3.6%, P<0.001) and non-HDL-C (−10.1% vs. 4.9%, P<0.001) levels were significantly greater in the ATOMEGA group (n=97) than in the atorvastatin group (n=103). Moreover, the proportion of total subjects reaching TG target of <200 mg/dL in the ATOMEGA group was significantly higher than that in the atorvastatin group (62.9% vs. 22.3%, P<0.001). The incidence of adverse events did not differ between the two groups.

Conclusion

The addition of OM3-FAs to atorvastatin improved TG and non-HDL-C levels to a significant extent compared to atorvastatin alone in subjects with residual hypertriglyceridemia.

Citations

Citations to this article as recorded by  
  • Association Between Omega‐3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose–Response Meta‐Analysis of Randomized Controlled Trials
    Tianjiao Wang, Xin Zhang, Na Zhou, Yuxuan Shen, Biao Li, Bingshu E. Chen, Xinzhi Li
    Journal of the American Heart Association.2023;[Epub]     CrossRef
  • Nutraceutical support in the prevention and treatment of cardiovascular diseases
    E. V. Gracheva, E. A. Starovoytova, E. S. Kulikov, N. A. Kirillova, S. V. Fedosenko, M. A. Balaganskaya, D. V. Kromka
    Rational Pharmacotherapy in Cardiology.2023; 19(3): 298.     CrossRef
  • Effect of coadministration of omega-3 fatty acids with glimepiride on glycemic control, lipid profile, irisin, and sirtuin-1 in type 2 diabetes mellitus patients: a randomized controlled trial
    Rehab H. Werida, Aalaa Ramzy, Youssri Nassief Ebrahim, Maged Wasfy Helmy
    BMC Endocrine Disorders.2023;[Epub]     CrossRef
  • The Effect of Dietary Interventions on Hypertriglyceridemia: From Public Health to Molecular Nutrition Evidence
    Karla Paulina Luna-Castillo, Xochitl Citlalli Olivares-Ochoa, Rocío Guadalupe Hernández-Ruiz, Iris Monserrat Llamas-Covarrubias, Saraí Citlalic Rodríguez-Reyes, Alejandra Betancourt-Núñez, Barbara Vizmanos, Erika Martínez-López, José Francisco Muñoz-Valle
    Nutrients.2022; 14(5): 1104.     CrossRef
  • The effect of omega-3 fatty acids and its combination with statins on lipid profile in patients with hypertriglyceridemia: A systematic review and meta-analysis of randomized controlled trials
    Yunjiao Yang, Wen Deng, Yanmei Wang, Tongyi Li, Yiding Chen, Cong Long, Qing Wen, Yue Wu, Qiu Chen
    Frontiers in Nutrition.2022;[Epub]     CrossRef
  • Comparison of the Efficacy and Safety of Atorvastatin 40 mg/ω-3 Fatty Acids 4 g Fixed-dose Combination and Atorvastatin 40 mg Monotherapy in Hypertriglyceridemic Patients who Poorly Respond to Atorvastatin 40 mg Monotherapy: An 8-week, Multicenter, Random
    Jong Shin Woo, Soon Jun Hong, Dong Hoon Cha, Kee Sik Kim, Moo Hyun Kim, Jun-Won Lee, Myung Ho Jeong, Jin-Ok Jeong, Jun-Hee Lee, Doo Soo Jeon, Eun Joo Cho, Soon Kil Kim, Jun Kwan, Chang Gyu Park, Hae Young Lee, Taek Jong Hong, Jinho Shin, Ho Joong Youn, Do
    Clinical Therapeutics.2021; 43(8): 1419.     CrossRef
  • All-Cause Mortality and Cardiovascular Death between Statins and Omega-3 Supplementation: A Meta-Analysis and Network Meta-Analysis from 55 Randomized Controlled Trials
    Jeongseon Kim, Tung Hoang, Ji-Myung Kim, So Young Bu, Jeong-Hwa Choi, Eunju Park, Seung-Min Lee, Eunmi Park, Ji Yeon Min, In Seok Lee, So Young Youn, Jee-Young Yeon
    Nutrients.2020; 12(10): 3203.     CrossRef
Clinical Diabetes & Therapeutics
Additional Effect of Dietary Fiber in Patients with Type 2 Diabetes Mellitus Using Metformin and Sulfonylurea: An Open-Label, Pilot Trial
Seung-Eun Lee, Yongbin Choi, Ji Eun Jun, You-Bin Lee, Sang-Man Jin, Kyu Yeon Hur, Gwang Pyo Ko, Moon-Kyu Lee
Diabetes Metab J. 2019;43(4):422-431.   Published online April 23, 2019
DOI: https://doi.org/10.4093/dmj.2018.0090
  • 5,132 View
  • 66 Download
  • 7 Citations
AbstractAbstract PDFPubReader   
Background

Metformin, sulfonylurea, and dietary fiber are known to affect gut microbiota in patients with type 2 diabetes mellitus (T2DM). This open and single-arm pilot trial investigated the effects of the additional use of fiber on glycemic parameters, insulin, incretins, and microbiota in patients with T2DM who had been treated with metformin and sulfonylurea.

Methods

Participants took fiber for 4 weeks and stopped for the next 4 weeks. Glycemic parameters, insulin, incretins during mixed-meal tolerance test (MMTT), lipopolysaccharide (LPS) level, and fecal microbiota were analyzed at weeks 0, 4, and 8. The first tertile of difference in glucose area under the curve during MMTT between weeks 0 and 4 was defined as ‘responders’ and the third as ‘nonresponders,’ respectively.

Results

In all 10 participants, the peak incretin levels during MMTT were higher and LPS were lower at week 4 as compared with at baseline. While the insulin sensitivity of the ‘responders’ increased at week 4, that of the ‘nonresponders’ showed opposite results. However, the results were not statistically significant. In all participants, metabolically unfavorable microbiota decreased at week 4 and were restored at week 8. At baseline, metabolically hostile bacteria were more abundant in the ‘nonresponders.’ In ‘responders,’ Roseburia intestinalis increased at week 4.

Conclusion

While dietary fiber did not induce additional changes in glycemic parameters, it showed a trend of improvement in insulin sensitivity in ‘responders.’ Even if patients are already receiving diabetes treatment, the additional administration of fiber can lead to additional benefits in the treatment of diabetes.

Citations

Citations to this article as recorded by  
  • The effects of prebiotics on gastrointestinal side effects of metformin in youth: A pilot randomized control trial in youth-onset type 2 diabetes
    Sydney A. Dixon, Sidharth Mishra, Katrina B. Dietsche, Shalini Jain, Lilian Mabundo, Michael Stagliano, Andrea Krenek, Amber Courville, Shanna Yang, Sara A. Turner, Abby G. Meyers, Doris E. Estrada, Hariom Yadav, Stephanie T. Chung
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • The impact of dietary, surgical, and pharmacological interventions on gut microbiota in individuals with diabetes mellitus: A systematic review
    Patricia M. Bock, Andreza F. Martins, Rafaela Ramalho, Gabriela H. Telo, Gabriel Leivas, Clara K. Maraschin, Beatriz D. Schaan
    Diabetes Research and Clinical Practice.2022; 189: 109944.     CrossRef
  • Assessment of the safety and probiotic properties of Roseburia intestinalis: A potential “Next Generation Probiotic”
    Chao Zhang, Kejia Ma, Kai Nie, Minzi Deng, Weiwei Luo, Xing Wu, Yujun Huang, Xiaoyan Wang
    Frontiers in Microbiology.2022;[Epub]     CrossRef
  • The Effect of Prebiotics and Oral Anti-Diabetic Agents on Gut Microbiome in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials
    Omorogieva Ojo, Xiaohua Wang, Osarhumwese Osaretin Ojo, Joanne Brooke, Yiqing Jiang, Qingqing Dong, Trevor Thompson
    Nutrients.2022; 14(23): 5139.     CrossRef
  • The Effect of Dietary Interventions on Chronic Inflammatory Diseases in Relation to the Microbiome: A Systematic Review
    Carlijn A. Wagenaar, Marieke van de Put, Michelle Bisschops, Wendy Walrabenstein, Catharina S. de Jonge, Hilde Herrema, Dirkjan van Schaardenburg
    Nutrients.2021; 13(9): 3208.     CrossRef
  • The Role of Dietary Fibre in Modulating Gut Microbiota Dysbiosis in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
    Omorogieva Ojo, Qian-Qian Feng, Osarhumwese Osaretin Ojo, Xiao-Hua Wang
    Nutrients.2020; 12(11): 3239.     CrossRef
  • High Fiber and Beta Carotene from Sweet Potatoes and Pumpkin Improve Insulin Resistance by Inhibition of Sterol Regulatory Binding Protein 1c in Liver of Hypertriglyceridemic Rats
    Sunarti Sunarti, Umar Santoso, Abrory Agus Cahya Pramana, Emy Huriyati, Dianandha Septiana Rubi
    Open Access Macedonian Journal of Medical Sciences.2020; 8(A): 898.     CrossRef
Clinical Diabetes & Therapeutics
Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus
You-Cheol Hwang, Ji Eun Jun, In-Kyung Jeong, Kyu Jeung Ahn, Ho Yeon Chung
Diabetes Metab J. 2019;43(5):582-589.   Published online January 16, 2019
DOI: https://doi.org/10.4093/dmj.2018.0124
  • 5,455 View
  • 167 Download
  • 11 Citations
AbstractAbstract PDFPubReader   
Background

The apolipoprotein B/A1 (apoB/A1) ratio is a stronger predictor of future cardiovascular disease than is the level of conventional lipids. Statin and ezetimibe combination therapy have shown additional cardioprotective effects over statin monotherapy.

Methods

This was a single-center, randomized, open-label, active-controlled study in Korea. A total of 36 patients with type 2 diabetes mellitus were randomized to either rosuvastatin monotherapy (20 mg/day, n=20) or rosuvastatin/ezetimibe (5 mg/10 mg/day, n=16) combination therapy for 6 weeks.

Results

After the 6-week treatment, low density lipoprotein cholesterol (LDL-C) and apoB reduction were comparable between the two groups (−94.3±15.4 and −62.0±20.9 mg/dL in the rosuvastatin group, −89.9±22.7 and −66.8±21.6 mg/dL in the rosuvastatin/ezetimibe group, P=0.54 and P=0.86, respectively). In addition, change in apoB/A1 ratio (−0.44±0.16 in the rosuvastatin group and −0.47±0.25 in the rosuvastatin/ezetimibe group, P=0.58) did not differ between the two groups. On the other hand, triglyceride and free fatty acid (FFA) reductions were greater in the rosuvastatin/ezetimibe group than in the rosuvastatin group (−10.5 mg/dL [interquartile range (IQR), −37.5 to 29.5] and 0.0 µEq/L [IQR, −136.8 to 146.0] in the rosuvastatin group, −49.5 mg/dL [IQR, −108.5 to −27.5] and −170.5 µEq/L [IQR, −353.0 to 0.8] in the rosuvastatin/ezetimibe group, P=0.010 and P=0.049, respectively). Both treatments were generally well tolerated, and there were no differences in muscle or liver enzyme elevation.

Conclusion

A 6-week combination therapy of low-dose rosuvastatin and ezetimibe showed LDL-C, apoB, and apoB/A1 ratio reduction comparable to that of high-dose rosuvastatin monotherapy in patients with type 2 diabetes mellitus. Triglyceride and FFA reductions were greater with the combination therapy than with rosuvastatin monotherapy.

Citations

Citations to this article as recorded by  
  • Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights
    Maya R Chilbert, Dylan VanDuyn, Sara Salah, Collin M Clark, Qing Ma
    Drug Design, Development and Therapy.2022; Volume 16: 2177.     CrossRef
  • Ezetimibe and diabetes mellitus:a new strategy for lowering cholesterol
    V.A. Serhiyenko, A.A. Serhiyenko
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2022; 18(5): 302.     CrossRef
  • The Effect of Rosuvastatin on Plasma/Serum Levels of High-Sensitivity C-Reactive Protein, Interleukin-6, and D-Dimer in People Living with Human Immunodeficiency Virus: A Systematic Review and Meta-Analysis
    Akililu Alemu Ashuro, Yin-Guang Fan, Yuan-Sheng Fu, Dong-Sheng Di, Napoleon Bellua Sam, Hai-Feng Pan, Dong-Qing Ye
    AIDS Research and Human Retroviruses.2021; 37(11): 821.     CrossRef
  • Comparison of the Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy and Rosuvastatin Monotherapy on Lipoprotein in Patients With Type 2 Diabetes: Multicenter Randomized Controlled Study
    Jiwoo Lee, You-Cheol Hwang, Woo Je Lee, Jong Chul Won, Kee-Ho Song, Cheol-Young Park, Kyu Jeung Ahn, Joong-Yeol Park
    Diabetes Therapy.2020; 11(4): 859.     CrossRef
  • Comparison of Renal Effects of Ezetimibe–Statin Combination versus Statin Monotherapy: A Propensity-Score-Matched Analysis
    Jaehyun Bae, Namki Hong, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Yong-ho Lee
    Journal of Clinical Medicine.2020; 9(3): 798.     CrossRef
  • Combined use of rosuvastatin and ezetimibe improves hepatic steatosis in patients with dyslipidemia
    Won Dong Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim
    European Journal of Gastroenterology & Hepatology.2020; 32(12): 1538.     CrossRef
  • Influence of rosuvastatin dose on total fatty acids and free fatty acids in plasma
    Cristian I. Ciucanu, Sonia Olariu, Daliborca C. Vlad, Victor Dumitraşcu
    Medicine.2020; 99(48): e23356.     CrossRef
  • The effect of switching from statin-monotherapy to statin/ezetimibe combination therapy on lipid profiles in patients with type 2 diabetes and dyslipidemia: a multicenter open-label study (EUCLID)
    Mitsuhide Takeshita, Atsushi Tanaka, Atsushi Kawaguchi, Keiko Sato, Shigeru Toyoda, Teruo Inoue, Koichi Node
    Vascular Failure.2020; 4(1): 22.     CrossRef
  • Response: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582–9)
    You-Cheol Hwang
    Diabetes & Metabolism Journal.2019; 43(6): 915.     CrossRef
  • Letter: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J2019;43:582–9)
    Tae Seo Sohn
    Diabetes & Metabolism Journal.2019; 43(6): 909.     CrossRef
  • Changes in Plasma Free Fatty Acids Associated with Type-2 Diabetes
    Amélie I. S. Sobczak, Claudia A. Blindauer, Alan J. Stewart
    Nutrients.2019; 11(9): 2022.     CrossRef
Obesity and Metabolic Syndrome
Utility of Serum Albumin for Predicting Incident Metabolic Syndrome According to Hyperuricemia
You-Bin Lee, Ji Eun Jun, Seung-Eun Lee, Jiyeon Ahn, Gyuri Kim, Jae Hwan Jee, Ji Cheol Bae, Sang-Man Jin, Jae Hyeon Kim
Diabetes Metab J. 2018;42(6):529-537.   Published online September 28, 2018
DOI: https://doi.org/10.4093/dmj.2018.0012
  • 4,025 View
  • 46 Download
  • 9 Citations
AbstractAbstract PDFSupplementary MaterialPubReader   
Background

Serum albumin and uric acid have been positively linked to metabolic syndrome (MetS). However, the association of MetS incidence with the combination of uric acid and albumin levels has not been investigated. We explored the association of albumin and uric acid with the risk of incident MetS in populations divided according to the levels of these two parameters.

Methods

In this retrospective longitudinal study, 11,613 non-MetS participants were enrolled among 24,185 individuals who had undergone at least four annual check-ups between 2006 and 2012. The risk of incident MetS was analyzed according to four groups categorized by the sex-specific medians of serum albumin and uric acid.

Results

During 55,407 person-years of follow-up, 2,439 cases of MetS developed. The risk of incident MetS increased as the uric acid category advanced in individuals with lower or higher serum albumin categories with hazard ratios (HRs) of 1.386 (95% confidence interval [CI], 1.236 to 1.554) or 1.314 (95% CI, 1.167 to 1.480). However, the incidence of MetS increased with higher albumin levels only in participants in the lower uric acid category with a HR of 1.143 (95% CI, 1.010 to 1.294).

Conclusion

Higher levels of albumin were associated with an increased risk of incident MetS only in individuals with lower uric acid whereas higher levels of uric acid were positively linked to risk of incident MetS regardless of albumin level.

Citations

Citations to this article as recorded by  
  • A predictive model for hyperuricemia among type 2 diabetes mellitus patients in Urumqi, China
    Palizhati Abudureyimu, Yuesheng Pang, Lirun Huang, Qianqian Luo, Xiaozheng Zhang, Yifan Xu, Liang Jiang, Patamu Mohemaiti
    BMC Public Health.2023;[Epub]     CrossRef
  • Synergistic Interaction between Hyperuricemia and Abdominal Obesity as a Risk Factor for Metabolic Syndrome Components in Korean Population
    Min Jin Lee, Ah Reum Khang, Yang Ho Kang, Mi Sook Yun, Dongwon Yi
    Diabetes & Metabolism Journal.2022; 46(5): 756.     CrossRef
  • Nutritional Biomarkers and Heart Rate Variability in Patients with Subacute Stroke
    Eo Jin Park, Seung Don Yoo
    Nutrients.2022; 14(24): 5320.     CrossRef
  • Mean and visit-to-visit variability of glycemia and left ventricular diastolic dysfunction: A longitudinal analysis of 3025 adults with serial echocardiography
    Jiyeon Ahn, Janghyun Koh, Darae Kim, Gyuri Kim, Kyu Yeon Hur, Sang Won Seo, Kyunga Kim, Jae Hyeon Kim, Jeong Hoon Yang, Sang-Man Jin
    Metabolism.2021; 116: 154451.     CrossRef
  • Can biomarkers be used to improve diagnosis and prediction of metabolic syndrome in childhood cancer survivors? A systematic review
    Vincent G. Pluimakers, Selveta S. van Santen, Marta Fiocco, Marie‐Christine E. Bakker, Aart J. van der Lelij, Marry M. van den Heuvel‐Eibrink, Sebastian J. C. M. M. Neggers
    Obesity Reviews.2021;[Epub]     CrossRef
  • Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
    Salim S. Virani, Alvaro Alonso, Emelia J. Benjamin, Marcio S. Bittencourt, Clifton W. Callaway, April P. Carson, Alanna M. Chamberlain, Alexander R. Chang, Susan Cheng, Francesca N. Delling, Luc Djousse, Mitchell S.V. Elkind, Jane F. Ferguson, Myriam Forn
    Circulation.2020;[Epub]     CrossRef
  • Association between dairy product consumption and hyperuricemia in an elderly population with metabolic syndrome
    Guillermo Mena-Sánchez, Nancy Babio, Nerea Becerra-Tomás, Miguel Á. Martínez-González, Andrés Díaz-López, Dolores Corella, Maria D. Zomeño, Dora Romaguera, Jesús Vioque, Ángel M. Alonso-Gómez, Julia Wärnberg, José A. Martínez, Luís Serra-Majem, Ramon Estr
    Nutrition, Metabolism and Cardiovascular Diseases.2020; 30(2): 214.     CrossRef
  • Evaluation of serum uric acid levels in patients with rosacea
    Nermin Karaosmanoglu, Engin Karaaslan, Pınar Ozdemir Cetinkaya
    Archives of Dermatological Research.2020; 312(6): 447.     CrossRef
  • Letter: Increased Serum Angiopoietin-Like 6 Ahead of Metabolic Syndrome in a Prospective Cohort Study (Diabetes Metab J 2019;43:521-9)
    Jin Hwa Kim
    Diabetes & Metabolism Journal.2019; 43(5): 727.     CrossRef
Epidemiology
High Proportion of Adult Cases and Prevalence of Metabolic Syndrome in Type 1 Diabetes Mellitus Population in Korea: A Nationwide Study
You-Bin Lee, Kyungdo Han, Bongsung Kim, Sang-Man Jin, Seung-Eun Lee, Ji Eun Jun, Jiyeon Ahn, Gyuri Kim, Jae Hyeon Kim
Diabetes Metab J. 2019;43(1):76-89.   Published online August 22, 2018
DOI: https://doi.org/10.4093/dmj.2018.0048
  • 5,115 View
  • 98 Download
  • 23 Citations
AbstractAbstract PDFSupplementary MaterialPubReader   
Background

The prevalence and incidence of type 1 diabetes mellitus (T1DM) in all age groups and the prevalence of metabolic syndrome in patients with T1DM in Korea were estimated.

Methods

The incidence and prevalence of T1DM between 2007 and 2013 were calculated using the Korean National Health Insurance Service (NHIS) datasets of claims. Clinical characteristics and prevalence of metabolic syndrome in individuals with T1DM between 2009 and 2013 were determined using the database of NHIS preventive health checkups.

Results

The prevalence of T1DM in Korea between 2007 and 2013 was 0.041% to 0.047%. The annual incidence rate of T1DM in Korea in 2007 to 2013 was 2.73 to 5.02/100,000 people. Although the incidence rate of typical T1DM was highest in teenagers, it remained steady in adults over 30 years of age. In contrast, the incidence rate of atypical T1DM in 2013 was higher in people aged 40 years or older than in younger age groups. Age- and sex-adjusted prevalence of metabolic syndrome in patients with T1DM was 51.65% to 55.06% between 2009 and 2013.

Conclusion

T1DM may be more common in Korean adults than previously believed. Metabolic syndrome may be a frequent finding in individuals with T1DM in Korea.

Citations

Citations to this article as recorded by  
  • Comparison of Insulin-Treated Patients with Ambiguous Diabetes Type with Definite Type 1 and Type 2 Diabetes Mellitus Subjects: A Clinical Perspective
    Insa Laspe, Juris J. Meier, Michael A. Nauck
    Diabetes & Metabolism Journal.2023; 47(1): 140.     CrossRef
  • Clinical and biochemical profile of childhood–adolescent-onset type 1 diabetes and adult-onset type 1 diabetes among Asian Indians
    Viswanathan Mohan, Ganesan Uma Sankari, Anandakumar Amutha, Ranjit Mohan Anjana, Saravanan Jeba Rani, Ranjit Unnikrishnan, Ulagamathesan Venkatesan, Coimbatore Subramanian Shanthi Rani
    Acta Diabetologica.2023; 60(4): 579.     CrossRef
  • Subtypes of type 2 diabetes and their association with outcomes in Korean adults - A cluster analysis of community-based prospective cohort
    You-Cheol Hwang, Hong-Yup Ahn, Ji Eun Jun, In-Kyung Jeong, Kyu Jeung Ahn, Ho Yeon Chung
    Metabolism.2023; 141: 155514.     CrossRef
  • Insulin Fact Sheet in Type 1 and 2 Diabetes Mellitus and Trends of Antidiabetic Medication Use in Insulin Users with Type 2 Diabetes Mellitus: 2002 to 2019
    Jiyun Park, Gyuri Kim, Bong-Sung Kim, Kyung-Do Han, So Yoon Kwon, So Hee Park, You-Bin Lee, Sang-Man Jin, Jae Hyeon Kim
    Diabetes & Metabolism Journal.2023; 47(2): 211.     CrossRef
  • Insulin resistance is more frequent in type 1 diabetes patients with long disease duration
    Yuting Xie, Mei Shi, Xiaolin Ji, Fansu Huang, Li Fan, Xia Li, Zhiguang Zhou
    Diabetes/Metabolism Research and Reviews.2023;[Epub]     CrossRef
  • Long-term Effectiveness of the National Diabetes Quality Assessment Program in South Korea
    Ji Hye Huh, Serim Kwon, Gui Ok Kim, Bo Yeon Kim, Kyoung Hwa Ha, Dae Jung Kim
    Diabetes Care.2023; 46(9): 1700.     CrossRef
  • Association between Metabolic Syndrome and Microvascular Complications in Chinese Adults with Type 1 Diabetes Mellitus
    Qianwen Huang, Daizhi Yang, Hongrong Deng, Hua Liang, Xueying Zheng, Jinhua Yan, Wen Xu, Xiangwen Liu, Bin Yao, Sihui Luo, Jianping Weng
    Diabetes & Metabolism Journal.2022; 46(1): 93.     CrossRef
  • The Incidence of Adult-Onset Type 1 Diabetes: A Systematic Review From 32 Countries and Regions
    Jessica L. Harding, Pandora L. Wander, Xinge Zhang, Xia Li, Suvi Karuranga, Hongzhi Chen, Hong Sun, Yuting Xie, Richard A. Oram, Dianna J. Magliano, Zhiguang Zhou, Alicia J. Jenkins, Ronald C.W. Ma
    Diabetes Care.2022; 45(4): 994.     CrossRef
  • Age at Diagnosis and the Risk of Diabetic Nephropathy in Young Patients with Type 1 Diabetes Mellitus
    Jong Ha Baek, Woo Je Lee, Byung-Wan Lee, Soo Kyoung Kim, Gyuri Kim, Sang-Man Jin, Jae Hyeon Kim
    Diabetes & Metabolism Journal.2021; 45(1): 46.     CrossRef
  • Genomic ancestry and metabolic syndrome in individuals with type 1 diabetes from an admixed population: a multicentre, cross‐sectional study in Brazil
    B. S. V. Barros, D. C. Santos, L. G. N. Melo, M. H. Pizarro, L. H. Muniz, D. A. Silva, L. C. Porto, M. B. Gomes
    Diabetic Medicine.2021;[Epub]     CrossRef
  • The Interplay Between Diet and the Epigenome in the Pathogenesis of Type-1 Diabetes
    Amira Kohil, Maha Al-Asmakh, Mashael Al-Shafai, Annalisa Terranegra
    Frontiers in Nutrition.2021;[Epub]     CrossRef
  • Risk of early mortality and cardiovascular disease according to the presence of recently diagnosed diabetes and requirement for insulin treatment: A nationwide study
    You‐Bin Lee, Kyungdo Han, Bongsung Kim, Min Sun Choi, Jiyun Park, Minyoung Kim, Sang‐Man Jin, Kyu Yeon Hur, Gyuri Kim, Jae Hyeon Kim
    Journal of Diabetes Investigation.2021; 12(10): 1855.     CrossRef
  • Age at Diagnosis and the Risk of Diabetic Nephropathy in Young Patients with Type 1 Diabetes Mellitus (Diabetes Metab J 2021;45:46-54)
    Ye Seul Yang, Tae Seo Sohn
    Diabetes & Metabolism Journal.2021; 45(2): 277.     CrossRef
  • Comparison of fracture risk between type 1 and type 2 diabetes: a comprehensive real-world data
    J. Ha, C. Jeong, K.-D. Han, Y. Lim, M.K. Kim, H.-S. Kwon, K.-H. Song, M.I. Kang, K.-H. Baek
    Osteoporosis International.2021; 32(12): 2543.     CrossRef
  • Early mortality and cardiovascular disease, varied association with body mass index and its changes in insulin-treated diabetes: a nationwide study
    You-Bin Lee, Bongsung Kim, Jiyun Park, Minyoung Kim, Min Sun Choi, Gyuri Kim, Sang-Man Jin, Kyu Yeon Hur, Kyungdo Han, Jae Hyeon Kim
    International Journal of Obesity.2021; 45(11): 2482.     CrossRef
  • Young-onset type 2 diabetes in South Korea: a review of the current status and unmet need
    Ye Seul Yang, Kyungdo Han, Tae Seo Sohn, Nam Hoon Kim
    The Korean Journal of Internal Medicine.2021; 36(5): 1049.     CrossRef
  • Positive association between the ratio of triglycerides to high-density lipoprotein cholesterol and diabetes incidence in Korean adults
    Joungyoun Kim, Sang-Jun Shin, Ye-Seul Kim, Hee-Taik Kang
    Cardiovascular Diabetology.2021;[Epub]     CrossRef
  • Mortality and causes of death in a population with blindness in Korea: A longitudinal follow-up study using a national sample cohort
    Hyo Geun Choi, Min Joung Lee, Sang-Mok Lee
    Scientific Reports.2020;[Epub]     CrossRef
  • Hospitalization for heart failure incidence according to the transition in metabolic health and obesity status: a nationwide population-based study
    You-Bin Lee, Da Hye Kim, Seon Mee Kim, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Yong Gyu Park, Kyungdo Han, Hye Jin Yoo
    Cardiovascular Diabetology.2020;[Epub]     CrossRef
  • Management of Type 1 Diabetes Mellitus in Adults
    Hye Ryoung Yun
    The Journal of Korean Diabetes.2020; 21(3): 156.     CrossRef
  • New Insulin Pumps and Open Source Artificial Pancreas System in Korea
    Jae Hyeon Kim
    The Journal of Korean Diabetes.2020; 21(4): 197.     CrossRef
  • Risk of early mortality and cardiovascular disease in type 1 diabetes: a comparison with type 2 diabetes, a nationwide study
    You-Bin Lee, Kyungdo Han, Bongsung Kim, Seung-Eun Lee, Ji Eun Jun, Jiyeon Ahn, Gyuri Kim, Sang-Man Jin, Jae Hyeon Kim
    Cardiovascular Diabetology.2019;[Epub]     CrossRef
  • Risk of end‐stage renal disease from chronic kidney disease defined by decreased glomerular filtration rate in type 1 diabetes: A comparison with type 2 diabetes and the effect of metabolic syndrome
    You‐Bin Lee, Kyungdo Han, Bongsung Kim, Ji Eun Jun, Seung‐Eun Lee, Jiyeon Ahn, Gyuri Kim, Sang‐Man Jin, Jae Hyeon Kim
    Diabetes/Metabolism Research and Reviews.2019;[Epub]     CrossRef
Complications
Color Doppler Ultrasonography Is a Useful Tool for Diagnosis of Peripheral Artery Disease in Type 2 Diabetes Mellitus Patients with Ankle-Brachial Index 0.91 to 1.40
Kyu Yeon Hur, Ji Eun Jun, Young Ju Choi, Yong-ho Lee, Dae Jung Kim, Seok Won Park, Byung Wook Huh, Eun Jig Lee, Sun-Ha Jee, Kap Bum Huh, Sung Hee Choi
Diabetes Metab J. 2018;42(1):63-73.   Published online February 23, 2018
DOI: https://doi.org/10.4093/dmj.2018.42.1.63
  • 4,972 View
  • 50 Download
  • 21 Citations
AbstractAbstract PDFPubReader   
Background

The clinical utility of ankle-brachial index (ABI) is not clear in subjects with less severe or calcified vessel. Therefore, we investigated the usefulness of color Doppler ultrasonography for diagnosing peripheral artery disease (PAD) in type 2 diabetes mellitus (T2DM) subjects.

Methods

We analyzed 324 T2DM patients who concurrently underwent ABI and carotid intima-media thickness (CIMT) measurements and color Doppler ultrasonography from 2003 to 2006. The degree of stenosis in patients with PAD was determined according to Jager's criteria, and PAD was defined as grade III (50% to 99% stenosis) or IV stenosis (100% stenosis) by color Doppler ultrasonography. Logistic regression analysis and receiver operating characteristic curve analysis were performed to evaluate the risk factors for PAD in patients with ABI 0.91 to 1.40.

Results

Among the 324 patients, 77 (23.8%) had ABI 0.91 to 1.40 but were diagnosed with PAD. Color Doppler ultrasonography demonstrated that suprapopliteal arterial stenosis, bilateral lesions, and multivessel involvement were less common in PAD patients with ABI 0.91 to 1.40 than in those with ABI ≤0.90. A multivariate logistic regression analysis demonstrated that older age, current smoking status, presence of leg symptoms, and high CIMT were significantly associated with the presence of PAD in patients with ABI 0.91 to 1.40 after adjusting for conventional risk factors. CIMT showed significant power in predicting the presence of PAD in patients with ABI 0.91 to 1.40.

Conclusion

Color Doppler ultrasonography is a useful tool for the detection of PAD in T2DM patients with ABI 0.91 to 1.40 but a high CIMT.

Citations

Citations to this article as recorded by  
  • Comparison of Color Doppler Ultrasound and Ankle-Brachial Pressure Index Measurement in Peripheral Vascular Diseases
    Shradha Gupta, Amit Mahajan, Anil Luther, Shubhra Rathore
    Indian Journal of Surgery.2023; 85(S1): 177.     CrossRef
  • Are portable ankle brachial pressure index measurement devices suitable for hypertension screening?
    Justyna Janus, Jennifer K. Nicholls, Edward Pallett, Matthew Bown, Emma M. L. Chung, Mohamed Yacin Sikkandar
    PLOS ONE.2023; 18(3): e0283281.     CrossRef
  • Clinical characteristics and risk factors of lower extremity amputation in the diabetic inpatients with foot ulcers
    Hongping Gong, Yan Ren, Zhenyi Li, Panpan Zha, Raju Bista, Yan Li, Dawei Chen, Yun Gao, Lihong Chen, Xingwu Ran, Chun Wang
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Diabetes mellitus and long-time outcomes of autovenous femoro-popliteal bypass
    A. S. Artemova, M. A. Chernyavskiy
    Diabetes mellitus.2023; 26(2): 182.     CrossRef
  • Association between carotid ultrasonographic parameters and microvascular and macrovascular complications in diabetes: A systematic review and meta-analysis
    Meimei Liao, Sen Chen, Ruiqiang Guo
    Journal of Diabetes and its Complications.2023; 37(8): 108554.     CrossRef
  • Effectiveness of bedside investigations to diagnose peripheral artery disease among people with diabetes mellitus: A systematic review
    Vivienne Chuter, Nicolaas Schaper, Joseph Mills, Robert Hinchliffe, David Russell, Nobuyoshi Azuma, Christian‐Alexander Behrendt, Edward J. Boyko, Michael S. Conte, Misty Humphries, Lee Kirksey, Katharine C. McGinigle, Sigrid Nikol, Joakim Nordanstig, Vin
    Diabetes/Metabolism Research and Reviews.2023;[Epub]     CrossRef
  • The intersocietal IWGDF, ESVS, SVS guidelines on peripheral artery disease in people with diabetes and a foot ulcer
    Robert Fitridge, Vivienne Chuter, Joseph Mills, Robert Hinchliffe, Nobuyoshi Azuma, Christian‐Alexander Behrendt, Edward J. Boyko, Michael S. Conte, Misty Humphries, Lee Kirksey, Katharine C. McGinigle, Sigrid Nikol, Joakim Nordanstig, Vincent Rowe, David
    Diabetes/Metabolism Research and Reviews.2023;[Epub]     CrossRef
  • The intersocietal IWGDF, ESVS, SVS guidelines on peripheral artery disease in people with diabetes mellitus and a foot ulcer
    Robert Fitridge, Vivienne Chuter, Joseph Mills, Robert Hinchliffe, Nobuyoshi Azuma, Christian-Alexander Behrendt, Edward J. Boyko, Michael S. Conte, Misty Humphries, Lee Kirksey, Katharine C. McGinigle, Sigrid Nikol, Joakim Nordanstig, Vincent Rowe, David
    Journal of Vascular Surgery.2023; 78(5): 1101.     CrossRef
  • Editor's Choice – The Intersocietal IWGDF, ESVS, SVS Guidelines on Peripheral Artery Disease in People With Diabetes Mellitus and a Foot Ulcer
    Robert Fitridge, Vivienne Chuter, Joseph Mills, Robert Hinchliffe, Nobuyoshi Azuma, Christian-Alexander Behrendt, Edward J. Boyko, Michael S. Conte, Misty Humphries, Lee Kirksey, Katharine C. McGinigle, Sigrid Nikol, Joakim Nordanstig, Vincent Rowe, David
    European Journal of Vascular and Endovascular Surgery.2023; 66(4): 454.     CrossRef
  • Peripheral Artery Disease: A Comprehensive Updated Review
    Garba Rimamskep Shamaki, Favour Markson, Demilade Soji-Ayoade, Chibuike Charles Agwuegbo, Michael Olaseni Bamgbose, Bob-Manuel Tamunoinemi
    Current Problems in Cardiology.2022; 47(11): 101082.     CrossRef
  • Reliability of bedside tests for diagnosing peripheral arterial disease in patients prone to medial arterial calcification: A systematic review
    Jeroen J.W.M. Brouwers, Siem A. Willems, Lauren N. Goncalves, Jaap F. Hamming, Abbey Schepers
    eClinicalMedicine.2022; 50: 101532.     CrossRef
  • Comparative Doppler ultrasound findings of foot arteries in patients with type 2 diabetes mellitus and normoglycaemic patients
    LatifatTunrayo Oduola-Owoo, AdekunleAyokunle Adeyomoye, OmodeleAbosede Olowoyeye, IfedayoAdeola Odeniyi, BukunmiMichael Idowu, BadmusBabatunde Oduola-Owoo, AdeniyiSunday Aderibigbe
    Journal of West African College of Surgeons.2022; 12(1): 55.     CrossRef
  • Reliability of Bedside Tests for Diagnosing Peripheral Arterial Disease in Patients Prone to Medial Arterial Calcification: A Systematic Review
    Jeroen Brouwers, Siem Willems, Lauren Goncalves, Jaap Hamming, Abbey Schepers
    SSRN Electronic Journal .2022;[Epub]     CrossRef
  • Estimating the diagnostic accuracy of the ankle–brachial pressure index for detecting peripheral arterial disease in people with diabetes: A systematic review and meta‐analysis
    V. H. Chuter, A. Searle, A. Barwick, J. Golledge, L. Leigh, C. Oldmeadow, B. Peterson, P. Tehan, S. M. Twigg
    Diabetic Medicine.2021;[Epub]     CrossRef
  • Prevalence of peripheral arterial disease and associated factors in people with type 2 diabetes
    Pedro José da Silva Filho, Elaine Cristina Martinez Teodoro, Elaine Cristina Alves Pereira, Vania Cristina dos Reis Miranda
    Fisioterapia em Movimento.2021;[Epub]     CrossRef
  • Peripheral Arterial Disease and Its Associated Factors among Type 2 Diabetes Mellitus Patients at Debre Tabor General Hospital, Northwest Ethiopia
    Yonas Akalu, Ambaye Birhan
    Journal of Diabetes Research.2020; 2020: 1.     CrossRef
  • Critical analysis and limitations of resting ankle-brachial index in the diagnosis of symptomatic peripheral arterial disease patients and the role of diabetes mellitus and chronic kidney disease
    Ali F. AbuRahma, Elliot Adams, Joseph AbuRahma, Luis A. Mata, L. Scott Dean, Cristyn Caron, Jennifer Sloan
    Journal of Vascular Surgery.2020; 71(3): 937.     CrossRef
  • Association of Time in Range levels with Lower Extremity Arterial Disease in patients with type 2 diabetes
    Jinfeng Li, Ya Li, Weiguo Ma, Yishan Liu, Xiaohong Yin, Chuanqing Xie, Jiao Bai, Min Zhang
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2020; 14(6): 2081.     CrossRef
  • The accuracy of toe brachial index and ankle brachial index in the diagnosis of lower limb peripheral arterial disease: A systematic review and meta-analysis
    Ángel Herraiz-Adillo, Iván Cavero-Redondo, Celia Álvarez-Bueno, Diana P. Pozuelo-Carrascosa, Montserrat Solera-Martínez
    Atherosclerosis.2020; 315: 81.     CrossRef
  • Exercise-induced calf muscle hyperemia: quantitative mapping with low-dose dynamic contrast enhanced magnetic resonance imaging
    Jeff L. Zhang, Gwenael Layec, Christopher Hanrahan, Christopher C. Conlin, Corey Hart, Nan Hu, Lillian Khor, Michelle Mueller, Vivian S. Lee
    American Journal of Physiology-Heart and Circulatory Physiology.2019; 316(1): H201.     CrossRef
  • Comparison of different methods of ABI acquisition for detection of peripheral artery disease in diabetic patients
    Miroslav Homza, Ondrej Machaczka, Martin Porzer, Milan Kozak, Jiri Plasek, David Sipula
    Biomedical Papers.2019; 163(3): 227.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal